Th17 cells are present at the site of inflammation in RA, Crohn's disease and psoriasis but the difference in the response to anti-IL-17 therapies strongly suggests that their direct implications in the pathogenesis of these diseases differ and reflect different effector functions in tissues. This evidence concerns the gene IL17A and psoriasis.